<p>隨着全球市場在謹慎的美聯儲評論和混合的經濟信號中航行，投資者越來越關注在不確定性中識別增長機會。在這樣的環境中，擁有高內部持股的公司往往脱穎而出，成為潛在的韌性參與者，因為這可以表明與業務最親近的人對其長期前景的強烈信心。</p>
<h3>全球高內部持股的十大增長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.9%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38%</td>
<td>63.7%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們高內部持股快速增長全球公司篩選器中的 847 只股票的完整列表。</p>
<p>在這裏，我們突出篩選器中我們首選股票的一個子集。</p>
<h2>蘇州澤璟生物製藥 (SHSE:688266)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 蘇州澤璟生物製藥有限公司是一家專注於創新藥物的研究、開發和商業化的生物製藥公司，市值約為 286.5 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其製藥部門產生收入，金額為 6.6791 億人民幣。</p>
<p><strong>內部持股：</strong> 29.4%</p>
<p><strong>收入增長預測：</strong> 每年 38%。</p>
<p>蘇州澤璟生物製藥展現出顯著的增長潛力，預計收入每年增長 38%，超過更廣泛的中國市場。儘管在 2025 年上半年淨虧損 7280 萬元人民幣，但收入同比增長至 3.7565 億元人民幣，較去年 2407 萬元人民幣有所上升。該股票的交易價格大幅低於其估計的公允價值，預計將在三年內實現盈利，儘管近期股價波動仍是投資者需要考慮的因素。</p>
<ul>
<li>在我們的收益增長報告中更詳細地瞭解蘇州澤璟生物製藥的潛力。</li>
<li>我們的估值報告揭示了蘇州澤璟生物製藥的股票可能以溢價交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688266 截至 2025 年 9 月的收益和收入增長</p>
<h2>北京瑞普科技 (SZSE:300593)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 北京瑞普科技有限公司在中國和國際上製造和銷售電源產品，市值為 100.9 億人民幣。</p>
<p><strong>運營：</strong> 北京瑞普科技有限公司從中國及全球範圍內的電源產品製造和銷售中產生收入。</p>
<p><strong>內部持股：</strong> 28.8%</p>
<p><strong>收入增長預測：</strong> 每年 32.7%。</p>
<p>北京瑞普科技有望實現顯著增長，預計收入每年增長 32.7%，超過更廣泛的中國市場增長率。儘管在 2025 年上半年報告淨虧損 9514 萬元人民幣，但公司顯示出前景，預測在三年內實現盈利。最近對其章程的修訂可能表明戰略轉變，儘管投資者應注意其高度波動的股價和低預期的股本回報率。</p>
<ul>
<li>通過我們的全面分析師估計報告深入瞭解北京瑞普科技的複雜性。</li>
<li>我們的全面估值報告提出了北京瑞普科技的定價可能高於其財務狀況所能合理化的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown"/></p>
<p>SZSE:300593 截至 2025 年 9 月的持股結構</p>
<h2>POCO 控股 (SZSE:300811)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> POCO 控股有限公司專注於合金軟磁粉和電子設備組件的開發、生產和銷售，市值為 217.1 億人民幣。</p>
<p><strong>運營：</strong> POCO 控股有限公司主要通過銷售合金軟磁粉、合金軟磁芯和相關電感組件為電子設備產生收入。</p>
<p><strong>內部持股：</strong> 24%</p>
<p><strong>收入增長預測：</strong> 每年 22.7%。</p>
<p>POCO 控股展現出作為增長公司的潛力，預計收入每年增長 22.7%，超過中國市場。儘管其股價波動和預期的股本回報率僅為 18.7%，但預計收益將顯著增長，每年增長 26.11%。最近對公司章程的修訂表明戰略變化，儘管過去三個月沒有報告重大內部交易活動。</p>
<ul>
<li>在我們的詳細增長預測報告中深入瞭解 POCO 控股的具體情況。</li>
<li>我們精心準備的估值報告暗示 POCO 控股的股價可能過高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300811 截至 2025 年 9 月的收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>點擊這裏解鎖我們 847 家快速增長全球公司高內部持股的全面列表。</li>
<li>對其他選擇感到好奇？特朗普的石油繁榮來了——管道準備好獲利。發現 22 只美國股票正在乘風破浪。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論僅基於歷史數據和分析師預測，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

鉑科新材

澤璟制藥-U

<p>隨着全球市場面臨不確定性，擁有高內部持股的公司因其增長潛力而受到關注。值得注意的公司包括蘇州澤璟製藥，預計年收入增長 38%，以及北京瑞博科技，預計增長 32.7%。鉑科控股預計收入增長 22.7%。儘管近期出現虧損，這些公司在未來盈利方面仍顯示出潛力，儘管股價波動仍然是投資者關注的問題</p>

<p>As global markets navigate a complex landscape marked by cautious Federal Reserve commentary and mixed economic signals, investors are increasingly focused on identifying growth opportunities amidst the uncertainty. In such an environment, companies with high insider ownership often stand out as potentially resilient players, as this can indicate strong confidence from those closest to the business in its long-term prospects.</p>
<div class="lb-trans"><p>隨着全球市場在謹慎的美聯儲評論和混合的經濟信號中航行，投資者越來越關注在不確定性中識別增長機會。在這樣的環境中，擁有高內部持股的公司往往脱穎而出，成為潛在的韌性參與者，因為這可以表明與業務最親近的人對其長期前景的強烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球高內部持股的十大增長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.9%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38%</td>
<td>63.7%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.9%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38%</td>
<td>63.7%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 847 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們高內部持股快速增長全球公司篩選器中的 847 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出篩選器中我們首選股票的一個子集。</p>
</div><h2>Suzhou Zelgen Biopharmaceuticals (SHSE:688266)</h2>
<div class="lb-trans"><h2>蘇州澤璟生物製藥 (SHSE:688266)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a biopharmaceutical company focused on the research, development, and commercialization of innovative drugs, with a market cap of approximately CN¥28.65 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 蘇州澤璟生物製藥有限公司是一家專注於創新藥物的研究、開發和商業化的生物製藥公司，市值約為 286.5 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its pharmaceuticals segment, amounting to CN¥667.91 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其製藥部門產生收入，金額為 6.6791 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 29.4%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 29.4%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 38% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 38%。</p>
</div><p>Suzhou Zelgen Biopharmaceuticals exhibits significant growth potential, with revenue forecasted to increase by 38% annually, outpacing the broader Chinese market. Despite a net loss of CNY 72.8 million in H1 2025, revenue rose to CNY 375.65 million from CNY 240.7 million year-on-year. The stock trades at a substantial discount to its estimated fair value and is expected to achieve profitability within three years, though recent share price volatility remains a consideration for investors.</p>
<div class="lb-trans"><p>蘇州澤璟生物製藥展現出顯著的增長潛力，預計收入每年增長 38%，超過更廣泛的中國市場。儘管在 2025 年上半年淨虧損 7280 萬元人民幣，但收入同比增長至 3.7565 億元人民幣，較去年 2407 萬元人民幣有所上升。該股票的交易價格大幅低於其估計的公允價值，預計將在三年內實現盈利，儘管近期股價波動仍是投資者需要考慮的因素。</p>
</div><ul>
<li>Take a closer look at Suzhou Zelgen Biopharmaceuticals' potential here in our earnings growth report.</li>
<li>Our valuation report unveils the possibility Suzhou Zelgen Biopharmaceuticals' shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的收益增長報告中更詳細地瞭解蘇州澤璟生物製藥的潛力。</li>
<li>我們的估值報告揭示了蘇州澤璟生物製藥的股票可能以溢價交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688266 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>SHSE:688266 截至 2025 年 9 月的收益和收入增長</p>
</div><h2>Beijing Relpow Technology (SZSE:300593)</h2>
<div class="lb-trans"><h2>北京瑞普科技 (SZSE:300593)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Beijing Relpow Technology Co., Ltd manufactures and sells power supply products both in China and internationally, with a market cap of CN¥10.09 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北京瑞普科技有限公司在中國和國際上製造和銷售電源產品，市值為 100.9 億人民幣。</p>
</div><p><strong>Operations:</strong> Beijing Relpow Technology Co., Ltd generates revenue from the manufacturing and sale of power supply products within China and on a global scale.</p>
<div class="lb-trans"><p><strong>運營：</strong> 北京瑞普科技有限公司從中國及全球範圍內的電源產品製造和銷售中產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 28.8%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 28.8%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 32.7% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 32.7%。</p>
</div><p>Beijing Relpow Technology is poised for substantial growth, with revenue expected to rise by 32.7% annually, surpassing the broader Chinese market's growth rate. Despite reporting a net loss of CNY 95.14 million in H1 2025, the company shows promise with forecasts indicating profitability within three years. Recent amendments to its articles of association may signal strategic shifts, though investors should be mindful of its highly volatile share price and low projected return on equity.</p>
<div class="lb-trans"><p>北京瑞普科技有望實現顯著增長，預計收入每年增長 32.7%，超過更廣泛的中國市場增長率。儘管在 2025 年上半年報告淨虧損 9514 萬元人民幣，但公司顯示出前景，預測在三年內實現盈利。最近對其章程的修訂可能表明戰略轉變，儘管投資者應注意其高度波動的股價和低預期的股本回報率。</p>
</div><ul>
<li>Navigate through the intricacies of Beijing Relpow Technology with our comprehensive analyst estimates report here.</li>
<li>Our comprehensive valuation report raises the possibility that Beijing Relpow Technology is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的全面分析師估計報告深入瞭解北京瑞普科技的複雜性。</li>
<li>我們的全面估值報告提出了北京瑞普科技的定價可能高於其財務狀況所能合理化的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown"/></p>
<p>SZSE:300593 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:300593 截至 2025 年 9 月的持股結構</p>
</div><h2>POCO Holding (SZSE:300811)</h2>
<div class="lb-trans"><h2>POCO 控股 (SZSE:300811)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> POCO Holding Co., Ltd. specializes in the development, production, and sale of alloy soft magnetic powder and components for electronic equipment, with a market cap of CN¥21.71 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> POCO 控股有限公司專注於合金軟磁粉和電子設備組件的開發、生產和銷售，市值為 217.1 億人民幣。</p>
</div><p><strong>Operations:</strong> POCO Holding Co., Ltd. generates revenue primarily from the sale of alloy soft magnetic powder, alloy soft magnetic core, and related inductance components for electronic equipment.</p>
<div class="lb-trans"><p><strong>運營：</strong> POCO 控股有限公司主要通過銷售合金軟磁粉、合金軟磁芯和相關電感組件為電子設備產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 24%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 24%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 22.7% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 22.7%。</p>
</div><p>POCO Holding demonstrates potential as a growth company, with revenue forecasted to grow at 22.7% annually, outpacing the Chinese market. Despite its volatile share price and low expected return on equity of 18.7%, earnings are projected to increase significantly at 26.11% per year. Recent amendments to the company's articles of association suggest strategic changes, though there is no substantial insider trading activity reported over the past three months.</p>
<div class="lb-trans"><p>POCO 控股展現出作為增長公司的潛力，預計收入每年增長 22.7%，超過中國市場。儘管其股價波動和預期的股本回報率僅為 18.7%，但預計收益將顯著增長，每年增長 26.11%。最近對公司章程的修訂表明戰略變化，儘管過去三個月沒有報告重大內部交易活動。</p>
</div><ul>
<li>Dive into the specifics of POCO Holding here with our thorough growth forecast report.</li>
<li>Our expertly prepared valuation report POCO Holding implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的詳細增長預測報告中深入瞭解 POCO 控股的具體情況。</li>
<li>我們精心準備的估值報告暗示 POCO 控股的股價可能過高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300811 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:300811 截至 2025 年 9 月的收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Unlock our comprehensive list of 847 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Curious About Other Options? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們 847 家快速增長全球公司高內部持股的全面列表。</li>
<li>對其他選擇感到好奇？特朗普的石油繁榮來了——管道準備好獲利。發現 22 只美國股票正在乘風破浪。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論僅基於歷史數據和分析師預測，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

三家全球增長型公司，內部人士持股比例高，預計收入增長 38%